These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 37746832)

  • 1. Diagnostic and therapeutic targeting of pathological tau proteins in neurodegenerative disorders.
    Sahara N; Higuchi M
    FEBS Open Bio; 2024 Feb; 14(2):165-180. PubMed ID: 37746832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.
    Ono M; Sahara N; Kumata K; Ji B; Ni R; Koga S; Dickson DW; Trojanowski JQ; Lee VM; Yoshida M; Hozumi I; Yoshiyama Y; van Swieten JC; Nordberg A; Suhara T; Zhang MR; Higuchi M
    Brain; 2017 Mar; 140(3):764-780. PubMed ID: 28087578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative In Vitro and In Vivo Quantifications of Pathologic Tau Deposits and Their Association with Neurodegeneration in Tauopathy Mouse Models.
    Ni R; Ji B; Ono M; Sahara N; Zhang MR; Aoki I; Nordberg A; Suhara T; Higuchi M
    J Nucl Med; 2018 Jun; 59(6):960-966. PubMed ID: 29419480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posttranslational Modifications Mediate the Structural Diversity of Tauopathy Strains.
    Arakhamia T; Lee CE; Carlomagno Y; Duong DM; Kundinger SR; Wang K; Williams D; DeTure M; Dickson DW; Cook CN; Seyfried NT; Petrucelli L; Fitzpatrick AWP
    Cell; 2020 Feb; 180(4):633-644.e12. PubMed ID: 32032505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer's and Non-Alzheimer's Disease Tauopathies.
    Tagai K; Ono M; Kubota M; Kitamura S; Takahata K; Seki C; Takado Y; Shinotoh H; Sano Y; Yamamoto Y; Matsuoka K; Takuwa H; Shimojo M; Takahashi M; Kawamura K; Kikuchi T; Okada M; Akiyama H; Suzuki H; Onaya M; Takeda T; Arai K; Arai N; Araki N; Saito Y; Trojanowski JQ; Lee VMY; Mishra SK; Yamaguchi Y; Kimura Y; Ichise M; Tomita Y; Zhang MR; Suhara T; Shigeta M; Sahara N; Higuchi M; Shimada H
    Neuron; 2021 Jan; 109(1):42-58.e8. PubMed ID: 33125873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overlaps and divergences between tauopathies and synucleinopathies: a duet of neurodegeneration.
    Li W; Li JY
    Transl Neurodegener; 2024 Mar; 13(1):16. PubMed ID: 38528629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vivo Visualization of Tau Accumulation, Microglial Activation, and Brain Atrophy in a Mouse Model of Tauopathy rTg4510.
    Ishikawa A; Tokunaga M; Maeda J; Minamihisamatsu T; Shimojo M; Takuwa H; Ono M; Ni R; Hirano S; Kuwabara S; Ji B; Zhang MR; Aoki I; Suhara T; Higuchi M; Sahara N
    J Alzheimers Dis; 2018; 61(3):1037-1052. PubMed ID: 29332041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A quantitative in vivo imaging platform for tracking pathological tau depositions and resultant neuronal death in a mouse model.
    Kimura T; Ono M; Seki C; Sampei K; Shimojo M; Kawamura K; Zhang MR; Sahara N; Takado Y; Higuchi M
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4298-4311. PubMed ID: 35798978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimer's Tauopathy.
    Murugan NA; Nordberg A; Ågren H
    ACS Chem Neurosci; 2021 Jul; 12(13):2437-2447. PubMed ID: 34152739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau Imaging in Neurodegenerative Diseases Using Positron Emission Tomography.
    Wang YT; Edison P
    Curr Neurol Neurosci Rep; 2019 Jun; 19(7):45. PubMed ID: 31172290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolutionarily conserved regulators of tau identify targets for new therapies.
    Kim J; de Haro M; Al-Ramahi I; Garaicoechea LL; Jeong HH; Sonn JY; Tadros B; Liu Z; Botas J; Zoghbi HY
    Neuron; 2023 Mar; 111(6):824-838.e7. PubMed ID: 36610398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new method to quantify tau pathologies with (11)C-PBB3 PET using reference tissue voxels extracted from brain cortical gray matter.
    Kimura Y; Endo H; Ichise M; Shimada H; Seki C; Ikoma Y; Shinotoh H; Yamada M; Higuchi M; Zhang MR; Suhara T
    EJNMMI Res; 2016 Dec; 6(1):24. PubMed ID: 26969002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau PET imaging: present and future directions.
    Saint-Aubert L; Lemoine L; Chiotis K; Leuzy A; Rodriguez-Vieitez E; Nordberg A
    Mol Neurodegener; 2017 Feb; 12(1):19. PubMed ID: 28219440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular and pathological heterogeneity of primary tauopathies.
    Chung DC; Roemer S; Petrucelli L; Dickson DW
    Mol Neurodegener; 2021 Aug; 16(1):57. PubMed ID: 34425874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An optimized reference tissue method for quantification of tau protein depositions in diverse neurodegenerative disorders by PET with
    Tagai K; Ikoma Y; Endo H; Debnath OB; Seki C; Matsuoka K; Matsumoto H; Oya M; Hirata K; Shinotoh H; Takahata K; Kurose S; Sano Y; Ono M; Shimada H; Kawamura K; Zhang MR; Takado Y; Higuchi M
    Neuroimage; 2022 Dec; 264():119763. PubMed ID: 36427751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development and validation of tau PET tracers: current status and future directions.
    Okamura N; Harada R; Ishiki A; Kikuchi A; Nakamura T; Kudo Y
    Clin Transl Imaging; 2018; 6(4):305-316. PubMed ID: 30148121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders.
    Maeda J; Zhang MR; Okauchi T; Ji B; Ono M; Hattori S; Kumata K; Iwata N; Saido TC; Trojanowski JQ; Lee VM; Staufenbiel M; Tomiyama T; Mori H; Fukumura T; Suhara T; Higuchi M
    J Neurosci; 2011 Mar; 31(12):4720-30. PubMed ID: 21430171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models.
    Silva MC; Ferguson FM; Cai Q; Donovan KA; Nandi G; Patnaik D; Zhang T; Huang HT; Lucente DE; Dickerson BC; Mitchison TJ; Fischer ES; Gray NS; Haggarty SJ
    Elife; 2019 Mar; 8():. PubMed ID: 30907729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting tauopathy with engineered tau-degrading intrabodies.
    Gallardo G; Wong CH; Ricardez SM; Mann CN; Lin KH; Leyns CEG; Jiang H; Holtzman DM
    Mol Neurodegener; 2019 Oct; 14(1):38. PubMed ID: 31640765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies.
    Orr ME; Sullivan AC; Frost B
    Trends Pharmacol Sci; 2017 Jul; 38(7):637-648. PubMed ID: 28455089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.